First-line camizestrant for ER+/HER2- advanced breast cancer

Mafalda Oliveira, SABCS 2022: Camizestrant vs fulvestrant for advanced ER+ HER2- breast cancerПодробнее

CAMBRIA 1: camizestrant ER+/HER2- early breast cancerПодробнее

CAMBRIA-1: camizestrant vs standard endocrine therapy in breast cancerПодробнее

5-Minute Journal Club: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastat...Подробнее

SERENA-2: camizestrant vs fulvestrant in post-menopausal women with advanced ER+/HER- breast cancerПодробнее

First-Line Treatment of HER2-Positive Metastatic Breast CancerПодробнее

Camizestrant may be superior to fulvestrant in patients with HR-positive, HER2-negative BCПодробнее

Capivasertib in Advanced Breast Cancer | NEJMПодробнее

Picking the right CDK 4/6 inhibitor upfront for metastatic breast cancer.Подробнее

Adjuvant treatment for high risk HR+ breast cancer | ESMO 2023 Breast Cancer HighlightsПодробнее

Dr. Richard Finn Discusses Palbociclib for Patients With Advanced Breast CancerПодробнее

Optimisation of Treatment Selection & Sequencing Decisions in ER+/HER2- Breast CancerПодробнее

Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancerПодробнее

SABCS 2022 highlightsПодробнее

Treatment decision making in first line metastatic ER+/Her2- BCПодробнее

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trialПодробнее

Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choicesПодробнее

SERD vs investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/mBCПодробнее

First-Line ER-Positive Metastatic Breast Cancer TreatmentsПодробнее